Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04999020
Registration number
NCT04999020
Ethics application status
Date submitted
4/08/2021
Date registered
10/08/2021
Date last updated
9/07/2025
Titles & IDs
Public title
Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
Query!
Scientific title
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Dermatomyositis
Query!
Secondary ID [1]
0
0
2021-001200-15
Query!
Secondary ID [2]
0
0
ALXN1210-DM-310
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Dermatomyositis
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Ravulizumab
Treatment: Drugs - Placebo
Experimental: Ravulizumab - Participants will receive ravulizumab in both Parts A and B.
Placebo comparator: Placebo - Participants will receive placebo in both Parts A and B.
Treatment: Drugs: Ravulizumab
Intravenous dosing will consist of a loading dose followed by maintenance doses administered every 8 weeks (q8w). The maintenance dosing will be initiated 2 weeks after the loading dose is administered.
Treatment: Drugs: Placebo
Intravenous dosing will consist of a loading dose followed by maintenance doses administered q8w. The maintenance dosing will be initiated 2 weeks after the loading dose is administered.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With International Myositis Assessment and Clinical Studies Total Improvement Score (IMACS-TIS) (TIS40) Response at Week 26 of the Randomized Controlled Period
Query!
Assessment method [1]
0
0
Data are presented for the number of participants with a TIS40 response, defined as an IMACS-TIS score = 40 at Week 26. IMACS-TIS is a clinical instrument that encompasses 6 core set measure (CSMs) (physician, patient, extra-muscular global activity, muscle strength, Health Assessment Questionnaire \[HAQ\], and muscle enzyme levels). A Total Improvement Score (TIS: 0-100), was determined by summing scores in each CSM, and was based on the improvement and relative weight of each CSM. A higher score indicated greater improvement. TIS40 was considered a moderate improvement score.
Query!
Timepoint [1]
0
0
Week 26
Query!
Secondary outcome [1]
0
0
TIS at Week 26
Query!
Assessment method [1]
0
0
TIS scores ranged from 0-100 with higher scores indicating a greater improvement. Scores were determined by summing scores in each of the 6 CSMs of the IMAC (physician, patient, extra-muscular global activity, muscle strength, HAQ, and muscle enzyme levels). Clinically meaningful thresholds for improvement were defined as = 20 point improvement response on IMACS-TIS (TIS20; mild), = 40 point improvement response on IMACS TIS (TIS40; moderate) and = 60 point improvement response on IMACS-TIS (TIS60; severe). Scores were based on the improvement and relative weight of each CSM. Data are presented for TIS (least squares mean) at Week 26.
Query!
Timepoint [1]
0
0
Week 26
Query!
Secondary outcome [2]
0
0
Change From Baseline In Cutaneous Dermatomyositis Disease Area And Severity Index (CDASI) Activity Score at Week 26
Query!
Assessment method [2]
0
0
The CDASI is an instrument that separately measures activity and damage in the skin of dermatomyositis (DM) participants. It contains 3 activity measures (erythema, scale, and erosion/ulceration) and 2 damage measures (poikiloderma and calcinosis). CDASI score is calculated by rating the severity of skin disease in 15 anatomical locations on the body based on the activity and damage components. CDASI was completed by the Clinician or Clinician-Investigator while examining the participant. Total CDASI scores ranged from 0-100, with higher scores indicating a greater disease severity. Change from baseline in CDASI Total Activity Score at Week 26 was analyzed using a mixed model repeated measures (MMRM). The MMRM model included the observed Total Activity Score values at post baseline visits (Week 26) as the dependent variable.
Query!
Timepoint [2]
0
0
Baseline, Week 26
Query!
Secondary outcome [3]
0
0
Number of Participants With Response Related to Muscle Enzymes: Normalization of Most Abnormal Baseline Enzyme at Week 26
Query!
Assessment method [3]
0
0
Laboratory tests were conducted to measure serum activities of muscle associated enzymes including creatine kinase (CK), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and aldolase. Data are presented for the number of participants who had an abnormal muscle enzyme at baseline that had been normalized at Week 26.
Query!
Timepoint [3]
0
0
Baseline, Week 26
Query!
Secondary outcome [4]
0
0
Change From Baseline In IMACS CSMs: Extra-Muscular Disease Activity Based on Myositis Disease Activity Assessment Tool (MDAAT) at Week 26
Query!
Assessment method [4]
0
0
The MDAAT assesses disease activity of extra-muscular organ systems and muscles in participants with DM. The validated MDAAT tool measures the degree of disease activity of extra-muscular organ systems and muscle on a 0-10 centimeter (cm) visual analog scale (VAS). Extra-muscular activity ranged between 0 and 10, where, 0 cm = absent and 10 cm = maximum disease activity.
Query!
Timepoint [4]
0
0
Baseline, Week 26
Query!
Secondary outcome [5]
0
0
Change From Baseline In IMACS CSMs: Physician Global Activity Assessment at Week 26
Query!
Assessment method [5]
0
0
The physician global activity assessment provides an overall rating of disease activity related to myositis. Disease activity is judged by the physician based on all information available at the time of evaluation, including the participant's appearance, medical history, physical examination, laboratory testing, and prescribed medical therapy. The global disease activity score is recorded on a 10-cm VAS, where 0 cm= no evidence of disease activity and 10 cm= extremely severe disease activity.
Query!
Timepoint [5]
0
0
Baseline, Week 26
Query!
Secondary outcome [6]
0
0
Change From Baseline In IMACS CSMs: Patient Global Activity Assessment at Week 26
Query!
Assessment method [6]
0
0
The patient global activity assessment provides an overall rating of disease activity related to myositis from the participant's perspective. Participants were asked to consider all of the active inflammation in their own muscles, skin, joints, intestines, heart, lungs, or other parts of the body that can improve with treatment. The patient global disease activity score was recorded on a 10-cm VAS that contained a smiley face at the 0-cm anchor and a sad face at the 10 cm anchor to help participants understand the scale. Scores ranged from 0 (no evidence of disease activity) to 10 (extremely active or severe disease activity).
Query!
Timepoint [6]
0
0
Baseline, Week 26
Query!
Secondary outcome [7]
0
0
Change From Baseline In IMACS CSMs: Manual Muscle Testing Subset 8 Muscles (MMT-8) at Week 26
Query!
Assessment method [7]
0
0
The purpose of the MMT-8 was to measure muscle strength as part of the physical examination. It included a subset of 8 muscle groups: neck flexors, deltoids, biceps, wrist, extensors, gluteus maximus and medius, quadriceps, and ankle dorsiflexors. Total MMT8 scores ranged from 0 (lowest strength) to 150 (highest strength).
Query!
Timepoint [7]
0
0
Baseline, Week 26
Query!
Secondary outcome [8]
0
0
Change From Baseline In IMACS CSMs: Health Assessment Questionnaire (HAQ) at Week 26
Query!
Assessment method [8]
0
0
The HAQ is a brief self-report questionnaire that assesses physical function pertaining to activities of daily living in a variety of domains. The HAQ includes 20 questions relating to 8 domains of function: dressing and grooming, arising, eating, walking, hygiene, reach, grip and usual activities. For each of the categories, participants reported the amount of difficulty they had in performing 2 or 3 specific subcategory items. The standard disability score is calculated from the 8 categories by dividing the sum of the individual categories by the number of categories answered, yielding a score from 0 (without any difficulty) to 3 (unable to do), with higher values indicating higher disability.
Query!
Timepoint [8]
0
0
Baseline, Week 26
Query!
Secondary outcome [9]
0
0
Number of Participants With CDASI Response (>=7-point Improvement) at Week 26
Query!
Assessment method [9]
0
0
The CDASI is an instrument that separately measures activity and damage in the skin of dermatomyositis (DM) participants. It contains 3 activity measures (erythema, scale, and erosion/ulceration) and 2 damage measures (poikiloderma and calcinosis). CDASI score is calculated by rating the severity of skin disease in 15 anatomical locations on the body based on the activity and damage components. CDASI was completed by the Clinician or Clinician-Investigator while examining the participant. Total CDASI scores ranged from 0-100, with higher scores indicating a greater disease severity. Data are presented for the number of participants with a CDASI response. Response was defined as a \>=7 point improvement in participants who did not have an intercurrent event at or prior to the relevant timepoint.
Query!
Timepoint [9]
0
0
Week 26
Query!
Secondary outcome [10]
0
0
Number of Participants With Cutaneous Dermatomyositis Activity Physician's Global Assessment (CDA-IGA) Response at Week 26
Query!
Assessment method [10]
0
0
CDA-IGA is a scale that was created to measure disease severity in participants with skin disease. It is a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) with morphologic descriptors for each score. The CDA-IGA was completed by the Investigator and was used to describe the overall appearance of lesions at a given time point. Data are presented for the number of participants with a CDA-IGA response at Week 26. A response was defined as participants with clear or almost clear skin (score of 0 or 1) who did not have an intercurrent event at or before the relevant timepoint.
Query!
Timepoint [10]
0
0
Week 26
Query!
Secondary outcome [11]
0
0
Number of Participants With = 20-Point Improvement Response on IMACS-TIS (TIS20) Response at Week 26
Query!
Assessment method [11]
0
0
TIS20 was defined as a =20-point improvement response on IMACS-TIS. IMACS-TIS is a clinical instrument that encompasses 6 CSMs (physician, patient, extra-muscular global activity, muscle strength, HAQ, and muscle enzyme levels). A Total Improvement Score (TIS: 0-100), was determined by summing scores in each CSM, and was based on the improvement and relative weight of each CSM. Higher scores indicated greater improvement/response. TIS20 is considered a mild improvement score.
Query!
Timepoint [11]
0
0
Week 26
Query!
Secondary outcome [12]
0
0
Number of Participants With = 60-Point Improvement Response on IMACS-TIS (TIS60) Response at Week 26
Query!
Assessment method [12]
0
0
TIS60 was defined as a =60-point improvement response on IMACS-TIS. IMACS-TIS is a clinical instrument that encompasses 6 CSMs (physician, patient, extra-muscular global activity, muscle strength, HAQ, and muscle enzyme levels). A Total Improvement Score (TIS: 0-100), was determined by summing scores in each CSM, and was based on the improvement and relative weight of each CSM. Higher scores indicated greater improvement/response. TIS60 is considered a severe improvement score.
Query!
Timepoint [12]
0
0
Week 26
Query!
Secondary outcome [13]
0
0
Time to First Response of TIS20, TIS40, or TIS60
Query!
Assessment method [13]
0
0
TIS20, 40 and 60 were defined as a =20, =40 and =60-point improvement response on IMACS-TIS respectively. IMACS-TIS is a clinical instrument that encompasses 6 CSMs (physician, patient, and extra-muscular global activity, muscle strength, HAQ, and muscle enzyme levels). A Total Improvement Score (TIS: 0-100), was determined by summing scores in each CSM, and was based on the improvement and relative weight of each CSM. Higher scores indicated greater improvement/response. TIS20, 40 and 60 were considered mild, moderate and severe improvement scores respectively. Data are presented for the time to first response of TIS20, TIS40, or TIS60. The median time to TIS20, TIS40, and TIS60 was defined at the time in which 50% of the participants experienced TIS20, TIS40, or TIS60, respectively, based on a Kaplan-Meier analysis.
Query!
Timepoint [13]
0
0
Baseline through Week 26
Query!
Secondary outcome [14]
0
0
Number of Participants With Clinical Worsening (CW) During the RCP At 2 Consecutive Visits
Query!
Assessment method [14]
0
0
CW was defined as one of the following: 1. Physician's global activity VAS worsening = 2 cm and MMT-8 worsening = 20% compared to baseline 2. Global extra muscular activity worsening = 2 cm on the MDAAT VAS compared to baseline 3. Any 3 of 5 CSMs (excluding muscle enzymes) worsening by = 30% compared to baseline Data are presented for the number of participants with clinical worsening during the RCP at 2 consecutive visits.
Query!
Timepoint [14]
0
0
Baseline through Week 26
Query!
Secondary outcome [15]
0
0
Number of Participants Who Received Acute Rescue Therapy With Standard DM Treatment
Query!
Assessment method [15]
0
0
Acute rescue therapy with standard DM treatment included an increased dose of a medication that was being taken for DM or the initiation of a new DM treatment (glucocorticoid and/or immunosuppressive/immunomodulatory therapy \[ISTs\]). Data are presented for the number of participants who received acute rescue therapy with standard DM treatment.
Query!
Timepoint [15]
0
0
Baseline through Week 26
Query!
Eligibility
Key inclusion criteria
Key
* 18 years of age or older at the time of signing the informed consent.
* Body weight = 30 kilograms at the time of Screening.
* Male or female.
* Diagnosis: Meet 2017 American College of Rheumatology/European League Against Rheumatism classification criteria for definite or probable DM.
* Participants who have an inadequate response or are intolerant to 1 or more DM treatments, including systemic corticosteroids or immunosuppressive/immunomodulatory therapies (for example, azathioprine, methotrexate, rituximab, intravenous immunoglobulin), either in combination or as monotherapy.
* Vaccinated against Neisseria meningitidis within 3 years prior to initiating ravulizumab as per national and local guidelines. Participants must receive the vaccination at least 2 weeks before first study intervention. The sponsor recommends that national and local guidelines for prophylactic antibiotics should also be followed.
* Female participants of childbearing potential and male participants must follow specified contraception guidance as described in the protocol.
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Participants who have been diagnosed with cancer within the last 3 years need to have appropriate negative cancer screening as per local standard of care within 6 months before Screening (basal or squamous cell skin cancer or carcinoma in situ of the cervix needs to have been excised and without evidence of residual disease for at least 3 months before Screening).
* Evidence of active malignant disease or malignancies diagnosed within the previous 3 years including hematological malignancies and solid tumors.
* Participants with other forms of myositis.
* As per investigator discretion, participants with significant muscle damage (for example, severe muscle atrophy, end stage muscle disease, MRI with severe atrophy or fibrofatty replacement)
* History of Neisseria meningitidis infection.
* Human immunodeficiency virus (HIV) infection (evidenced by HIV Type 1 or Type 2 antibody titer).
* Active systemic bacterial, viral, or fungal infection within 14 days prior to ravulizumab administration.
* Presence of fever = 38°Celsius (100.4°Fahrenheit) within 7 days prior to study drug administration on Day 1.
* History of hypersensitivity to murine proteins or to 1 of the excipients of ravulizumab.
* Pregnant, breastfeeding, or intending to conceive during the course of the study.
* Inability or unwillingness to adhere to the protocol requirements.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
19/11/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
8/05/2024
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
38
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Camperdown
Query!
Recruitment hospital [2]
0
0
Research Site - Murdoch
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
WA6150 - Murdoch
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
District of Columbia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kansas
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Nevada
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
North Carolina
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Ohio
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Pennsylvania
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
South Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Tennessee
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Washington
Query!
Country [18]
0
0
Brazil
Query!
State/province [18]
0
0
Belo Horizonte
Query!
Country [19]
0
0
Brazil
Query!
State/province [19]
0
0
Belém
Query!
Country [20]
0
0
Brazil
Query!
State/province [20]
0
0
Campinas
Query!
Country [21]
0
0
Brazil
Query!
State/province [21]
0
0
Juiz de Fora
Query!
Country [22]
0
0
Brazil
Query!
State/province [22]
0
0
Natal
Query!
Country [23]
0
0
Brazil
Query!
State/province [23]
0
0
Porto Alegre
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
Salvador
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Sao Jose Do Rio Preto
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Serra
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
São Paulo
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Vitória
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Lille
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Lyon
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Nantes cedex 1
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Paris Cedex 13
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Paris
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Strasbourg
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Toulouse
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Duesseldorf
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Erlangen
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Essen
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Freiburg im Breisgau
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Goettingen
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Halle
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Jena
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Bari
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Brescia
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Catania
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Firenze
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Jesi
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Messina
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Milano
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Pavia
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Pisa
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Reggio Emilia
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Roma
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Rome
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Rozzano
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Siena
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Torino
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Torrette AN
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Udine
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Verona
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Bunkyo-ku
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Hiroshima-shi
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Iruma-Gun
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Nagoya-shi
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Narita-shi
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Okayama
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Osaka
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Sapporo-shi
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Sendai-shi
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Urayasu-shi
Query!
Country [71]
0
0
Korea, Republic of
Query!
State/province [71]
0
0
Daejeon
Query!
Country [72]
0
0
Korea, Republic of
Query!
State/province [72]
0
0
Jung-gu
Query!
Country [73]
0
0
Korea, Republic of
Query!
State/province [73]
0
0
Seoul
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
Warszawa
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
A Coruna
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Barakaldo
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Barcelona
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Bilbao (Vizcaya)
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
L'Hospitalet de Llobregat
Query!
Country [80]
0
0
Spain
Query!
State/province [80]
0
0
Las Palmas de Gran Canaria
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
Madrid
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Oviedo
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Santander
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Sevilla
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Valencia
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Zaragoza
Query!
Country [87]
0
0
Taiwan
Query!
State/province [87]
0
0
Kaohsiung City
Query!
Country [88]
0
0
Taiwan
Query!
State/province [88]
0
0
Taichung
Query!
Country [89]
0
0
Taiwan
Query!
State/province [89]
0
0
Taoyuan City
Query!
Country [90]
0
0
Turkey
Query!
State/province [90]
0
0
Altindag-Ankara
Query!
Country [91]
0
0
Turkey
Query!
State/province [91]
0
0
Istanbul
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
Edinburgh
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Liverpool
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
London
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Salford
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
West Bromwich
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Alexion Pharmaceuticals, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a Phase 2/3, double-blind, randomized, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in adult participants with dermatomyositis (DM).
Query!
Trial website
https://clinicaltrials.gov/study/NCT04999020
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/20/NCT04999020/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/20/NCT04999020/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT04999020
Download to PDF